DATA GRAPHICS | Product Development
Sinopharm’s COVID-19 vaccine data add to early picture of correlates of protection: Data Byte
First Phase III win for an inactivated virus vaccine against COVID-19
December 10, 2020 2:14 AM UTC
A third vaccine modality has shown efficacy in preventing COVID-19 and the data, though sparse, shed more light on the neutralizing antibodies needed to confer protection against the virus.
The United Arab Emirates’ Ministry of Health and Prevention announced Wednesday that an inactivated virus vaccine from China National Biotech Group Corp. (Sinopharm) led to an 86% protection rate in a Phase III trial in 31,000 subjects, and 100% protection rate in preventing moderate and severe disease. The UAE has granted the vaccine emergency use authorization...